September 06, 2013
1 min read

ThromboGenics, Bicycle Therapeutics enter exclusive agreement covering new approach to DME treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

ThromboGenics has acquired exclusive rights to develop and commercialize treatments based on Bicycle Therapeutics’ bicyclic peptides that may offer the potential to improve treatment of diabetic macular edema, according to a news release.

The companies will work together on preclinical development of the bicyclic peptide inhibitors as part of the collaboration and license agreement, the release said.

“We have used the Bicycle technology platform to identify and optimize highly selective bicyclic peptides that inhibit a target involved in vascular permeability in the picomolar range,” Rolf Günther, MD, PhD, CEO of Bicycle Therapeutics, said in the release. “I … look forward, in time, to progressing drug candidates into the clinic.”

The agreement involves ThromboGenics paying an undisclosed upfront fee along with development and regulatory milestone payments and royalties on sales of potential products, according to the release.